SuperworthMimedx profit margin MDXG
Gross, operating and net profit as a share of revenue over the last twelve months, from 2012.
- Net margin, 12 months
- 1.8%
- Operating margin, 12 months
- 2.5%
- Net margin on a year earlier
- −7.1 pts
- Peer median
- 6.5%
Over the twelve months to Jun 30, 2026, Mimedx kept 1.8% of its revenue as net profit, with an operating margin of 2.5% and a gross margin of 78.8%.
Five years earlier its net margin was −17.7%.
The median for 10 medical instruments and supplies stocks of a similar size is 6.5%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 11.6% | 15.3% | 82.6% |
| FY2024 | 12.2% | 16.9% | 82.8% |
| FY2023 | 18.1% | 11.5% | 83.0% |
| FY2022 | −11.3% | −9.3% | 82.0% |
| FY2021 | −4.0% | −1.9% | 83.3% |
| FY2020 | −19.9% | −18.3% | 84.2% |
| FY2019 | −8.5% | −7.1% | 85.6% |
| FY2018 | −8.3% | −1.1% | 89.9% |
| FY2017 | 20.2% | n/a | 89.0% |
| FY2016 | 4.9% | 7.5% | 86.8% |
| FY2015 | 15.7% | 13.0% | 89.2% |
| FY2014 | 5.3% | 6.0% | 89.3% |
| FY2013 | −6.9% | −4.5% | 84.2% |
| FY2012 | −28.3% | −19.8% | 80.8% |
| FY2011 | n/a | n/a | 56.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 1.8% | −7.1 pts | 2.5% | |
| Q1 FY26 | 7.9% | −3.5 pts | 10.2% | |
| Q4 FY25 | 11.6% | −0.6 pts | 15.3% | |
| Q3 FY25 | 10.4% | −15.4 pts | 13.7% | |
| Q2 FY25 | 8.8% | −17.3 pts | 11.8% | |
| Q1 FY25 | 11.4% | −10.3 pts | 15.3% | |
| Q4 FY24 | 12.2% | −6.0 pts | 16.9% | |
| Q3 FY24 | 25.8% | +24.4 pts | 18.5% | |
| Q2 FY24 | 26.1% | +30.4 pts | 18.6% | |
| Q1 FY24 | 21.7% | +30.5 pts | 15.1% | |
| Q4 FY23 | 18.1% | +29.4 pts | 11.5% | |
| Q3 FY23 | 1.4% | +12.0 pts | 7.3% |
Against its peers
Companies in Medical - Instruments & Supplies nearest Mimedx's size, closest first, today.
| Company | Profit margin |
|---|---|
| MDXGMimedx | 1.8% |
| TCMDTactile Systems Technology | 7.1% |
| MOVMovado | 6.0% |
| EMBCEmbecta | 8.6% |
| IRMDIradimed | 26.7% |
| STAAStaar Surgical | 1.1% |
| INFUInfuSystem | 6.0% |
| BVSBioventus | 9.4% |
| CDRECadre | 5.3% |
| UTMDUtah Medical Products | 29.0% |
| EYENational Vision | 2.5% |
| Peer median | 6.5% |
Where Mimedx ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Mimedx
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.